Skip to main content
ENDO 2026 Main banner

Diabetes and Vascular Disease

SAT-620 - Alyteserin-2A Improved Glucose Tolerance, Insulin Secretion and Insulin Sensitivity in Mice with Diet-Induced Obesity-Diabetes

Saturday, June 13, 2026
9:30 AM - 4:30 PM CT
Location: ENDOExpo; Poster Floor


Aim: Alyteserin-2a has been previously reported to exhibit in vitro and acute in vivo insulin-releasing and glucose-lowering effects. However, data on its long-term effects is lacking. This study investigated long-term effects of alyteserin-2a on animals with diet-induced obesity-diabetes.

Methods: High fat-fed mice received daily injections of alyteserin-2a for 15 days. Non-fasting blood glucose, plasma insulin and body weight were monitored every 72 h. After the treatment, glucose tolerance, insulin secretion, insulin sensitivity as well as liver and kidney function were assessed in treated mice.

Results: Daily intraperitoneal administration of alyteserin-2a (75 nmol/kg bw) significantly reduced non-fasting glucose levels (26.3%, P< 0.01) and plasma insulin-levels (1.3-fold, P< 0.01) as from day 3 of treatment. Glucose tolerance at the end of the treatment improved by 36.7% (P < 0.001) and insulin secretion improved by 1.5-fold (P < 0.01) compared to untreated animals. Alyteserin-2a improved insulin sensitivity by 1.4-fold (P < 0.01) but produced no significant effect on body weight of treated mice. Reduced plasma levels of enzyme markers of liver toxicity (AST, ALT and ALP, 20.5 – 30.5%, P< 0.001 – 0.01) and kidney injury (creatinine, 31.4%, P< 0.01) was observed in peptide-treated mice.

Conclusion: These results indicate beneficial long-term effects of alyteserin-2a in animal models of type 2 diabetes and encourages its further pre-clinical development

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*